AIM To explore the feasibility of early gastric cancer diagnosis with 2LC reagent, and to establish a grossexploration method for early gastric cancer with the reagent based on the feasibility.METHODS Add 30 mg or 0.3 mL 2LC reagent into 5 mL urinary sample, observe the change of urinary,and analyze the sample on DAO-JIN-UV-260 Ultraviolet-analyzer at 190nm - 700nm, then, record theabsorbance at 490nm. To determine best stage of sample, take some samples on 8:00 pm and 8:00 am,respectively. To select best dosage of 2LC, take the test with different concentrations. To test the effect ofoperation, conduct the experiment in different stages before and after the operation for the patients withgastric cancer. Two parallel samples were taken each time in the whole experiment.RESULTS Red compound produced by some reactions when the 2LC reagent was added into the urinary ofpatients with gastric cancer, and the urine had obvious absorptivity at about 490nm (positive). There was almost no reaction in the urine of other samples (negative). A total of 172 samples were tested, the positiverate of gastric cancer was above 90% in 48 samples before the operation, in which 8 advanced gastric cancerand 9 early stage gastric cancer samples behaved stronger positive reaction. The positive rate of 118 othersamples was less than 10%. The urine taken in the morning was batter than that in the evening. The bestdosage of 2LC was 6 mg/mL for crystal and 0.05 mL/mL for liquid. The test results of gastric cancerpatients with postoperative tumor recrudescence or transfer were positive, and the others were negative.CONCLUSION There is a high feasibility in manipulation simplification, specificity and receptivity of 2LCreagent for early gastric cancer detection, and the characteristics mentioned above will be improved based onthe advanced raw material used and the style of the 2LC reagent. It is an effective gross exploration methodfor early gastric cancer with the 2LC reagent, and can determine the effect of operation for the gastriccancer.

膀胱癌患者血清、尿液及组织基质金属蛋白酶及其抑制剂的变化

目的:研究膀胱癌患者血清、尿液及组织基质金属蛋白酶及其抑制剂的变化情况.方法:选取本院收治的64例膀胱癌患者为观察组,另选取64例同期的膀胱良性病变患者为对照组,然后将两组的血清、尿液及组织基质金属蛋白酶及其抑制剂进行检测及比较,并比较观察组中不同分类与分期患者的检测结果.结果:观察组基质金属蛋白酶及其抑制剂的血清、尿液水平和组织阳性率均高于对照组,且不同分期者之间比较,差异具有统计学意义(P＜0.05);而观察组中不同分类者比较,差异无统计学意义(P＞0.05).结论:膀胱癌患者血清、尿液及组织基质金属蛋白酶及其抑制剂均呈现高表达状态,并且疾病的诊断及治疗效果的监测均有较高的临床价值.